Greater Glasgow and Clyde Medicines

MHRA Drug Safety Update August 2021

DAAs should be continued during the hospital stay, unless the clinical condition of the patient precludes administration.

This post summarises the latest NHS Greater Glasgow and Clyde decisions relating to new medicines assessed by SMC and considered by the Area Drug and Therapeutics Committee (ADTC) and uses a nationally developed format specifically aimed for patients and the public.

For full details of the medicines included in this post that are available for use, including any restrictions on prescribing, please see the relevant entry in the GGC Formulary

This update covers local formulary changes and decisions not related to recent SMC advice such as formulary appeals, new drug assessments and formulary section reviews click here

This post summarises the latest NHS Greater Glasgow and Clyde decisions relating to new medicines assessed by SMC and considered by the Area Drug and Therapeutics Committee (ADTC) and uses a nationally developed format specifically aimed for patients and the public.

For full details of the medicines included in this post that are available for use, including any restrictions on prescribing, please see the relevant entry in the GGC Formulary

This update covers local formulary changes and decisions not related to recent SMC advice such as formulary appeals, new drug assessments and formulary section reviews.

Management of palliative patients with Parkinson’s disease (PD) approaching end of life who are normally maintained on oral PD medicines

This post summarises the latest NHS Greater Glasgow and Clyde decisions relating to new medicines assessed by SMC and considered by the Area Drug and Therapeutics Committee (ADTC) and uses a nationally developed format specifically aimed for patients and the public.

For full details of the medicines included in this post that are available for use, including any restrictions on prescribing, please see the relevant entry in the GGC Formulary

Management of Parkinson’s disease (PD) medicines in patients undergoing elective surgery who are normally maintained on oral PD medicines.

This update covers local formulary changes and decisions not related to recent SMC advice such as formulary appeals, new drug assessments and formulary section reviews